MarketFriction

Sakar Healthcare Ltd

NSE SAKAR · Pharmaceuticals
₹1,075.00 -1.65%
NSE close2026-10-01
52 week range345.50 - 1,229.85
Market cap₹2,496 Cr.
P/E69.2
IPO 2016 · +2050% since ASM long-term Price band 20% Delivery 43.5%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales343743414343505358707173
Expenses252832303132354046524552
Operating Profit9911111212161311192621
OPM %27%24%25%26%27%27%31%24%20%26%37%29%
Other Income101000001102
Interest222121422222
Depreciation445555566667
Profit before tax435555655111815
Tax %13%31%35%49%6%17%8%13%15%6%39%29%
Net Profit423255655101110
EPS in Rs1.700.951.431.112.212.062.622.102.044.614.954.62
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales414453688395128133153178251272
Expenses33344051637299100115128182195
Operating Profit81013172023293338506977
OPM %20%23%24%25%24%24%23%25%25%28%27%28%
Other Income010121253123
Interest333222368987
Depreciation334678101518212425
Profit before tax35691213191716224049
Tax %22%30%38%28%21%19%20%24%27%19%23%
Net Profit23471011151312183036
EPS in Rs2.783.083.124.476.436.848.906.705.377.9713.7016.22
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth20%22%24%44%
Compounded Profit Growth30%23%34%82%
Stock Price CAGR%48%49%219%
Return on Equity9%8%7%10%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital8811121515161719222222
Reserves7112539576683110154241264302
Borrowings2522241111174393119798671
Other Liabilities111011181517374744474386
Total Liabilities5051718197115178268336389415481
Fixed Assets36374953646669205267314309326
CWIP000091349160174
Investments000000073000
Other Assets1414222825366055607490151
Total Assets5051718197115178268336389415481
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity49251619153633243449
Cash from Investing Activity-1-4-14-8-25-22-47-90-74-52-31-28
Cash from Financing Activity-3-613-139332554127-3-21
Net Cash Flow1-10-160-0-0-000-0-0
Free Cash Flow45-13-4-9-4-32-62-49-35221
CFO/OP60%117%30%51%104%110%67%121%113%72%73%77%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days212644745136484060506373
Inventory Days1421071145170921126976121193207
Days Payable20665157414614114912912093153
Cash Conversion Cycle1436710768808319-39751163127
Working Capital Days2710679831312-11-6295245
ROCE %14%14%15%14%16%16%13%12%9%7%9%12%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters54.15%53.15%53.15%53.15%53.15%53.58%53.58%52.86%52.86%52.86%52.86%52.52%
FIIs14.03%13.76%13.52%13.52%13.42%13.58%13.61%13.41%13.31%13.05%12.94%12.13%
DIIs10.82%10.62%10.62%10.62%10.62%10.88%10.97%11.25%11.43%11.36%11.32%11.37%
Public21.00%22.47%22.71%22.71%22.80%21.96%21.85%22.48%22.41%22.73%22.87%23.98%
No. of Shareholders7,2997,0017,3867,3137,8678,5988,6088,1157,5657,0699,58014,734

Fundamentals

Market Cap₹ 2,496 Cr.
Current Price₹ 1,122
Stock P/E69.2
Book Value₹ 146
ROCE12.4 %
ROE9.99 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)44%
Compounded Profit Growth (TTM)82%
Standalone figures.
Valuation
Market capRs 2,392 Cr
Enterprise valueRs 2,462 Cr
P/E (TTM)66.28x
Price to book7.37x
Price to sales8.79x
EV / EBITDA30.44x
EV / EBIT43.69x
EV / sales9.05x
Price to cash flow48.56x
Earnings yield1.51%
P/E, 3-year average43.86x
P/B, 3-year average2.70x
P/E, 5-year average35.34x
P/B, 5-year average2.42x
Profitability
Operating margin (excl. other income)27.41%
Operating margin (incl. other income)28.32%
EBITDA margin29.74%
Pre-tax margin18.00%
Net profit margin13.27%
Net margin, latest quarter14.09%
ROE9.99%
ROCE12.42%
ROA6.80%
ROE, 3-year average7.24%
ROCE, 3-year average9.42%
ROA, 3-year average4.79%
ROE, 5-year average8.74%
ROCE, 5-year average9.85%
ROA, 5-year average5.09%
ROIC (approx.)10.95%
Tax rate23.31%
Other income / net worth0.71%
Growth
Sales growth (latest year)41.55%
Profit growth (latest year)74.17%
Sales CAGR, 3 years23.52%
Sales CAGR, 5 years21.55%
Profit CAGR, 3 years33.68%
Profit CAGR, 5 years23.31%
Sales growth QoQ2.63%
Profit growth QoQ-6.72%
Sales growth YoY (latest quarter)38.36%
Profit growth YoY (latest quarter)120.13%
Per share
EPS (TTM)Rs 16.22
EPS (latest year)Rs 13.70
EPS (latest quarter)Rs 4.62
EPS, 3-year averageRs 9.01
EPS, 5-year averageRs 8.53
Book value per shareRs 145.86
Sales per shareRs 122.23
Cash flow per shareRs 22.14
Free cash flow per shareRs 9.44
Efficiency
Asset turnover0.52x
Fixed asset turnover0.77x
Inventory turnover1.88x
Inventory days194 days
Debtor days73 days
Debtors turnover5.02x
Creditor days153 days
Cash conversion cycle127 days
Working capital days45 days
Leverage
Total debtRs 71 Cr
Cash and bankRs 0 Cr
Net debtRs 70 Cr
Debt to equity0.22x
Net debt / EBITDA0.87x
Interest coverage7.63x
Current ratio (filing 2026-03-31)1.28x
Quick ratio (filing 2026-03-31)0.64x
Trade payables (filing 2026-03-31)Rs 52 Cr
Owners' fund to total sources67.46%
Debt to assets14.66%
Cash flow
Cash from Operating Activity (latest year)Rs 49 Cr
Cash from Investing Activity (latest year)Rs -28 Cr
Cash from Financing Activity (latest year)Rs -21 Cr
Net Cash Flow (latest year)Rs -0 Cr
Free cash flow (latest year)Rs 21 Cr
FCFE (approx.: FCF + change in debt)Rs 5 Cr
Cash from ops / profit, 5 years2.00x
Sales to cash flow5.10x
Statement figures
Net sales (TTM)Rs 272 Cr
Net sales (latest year)Rs 251 Cr
Sales (latest quarter)Rs 73 Cr
Operating profit excl. other income (latest year)Rs 69 Cr
Operating profit (latest quarter)Rs 21 Cr
Other income (TTM)Rs 3 Cr
EBITDA (TTM)Rs 81 Cr
PBDT (TTM)Rs 73 Cr
Profit before tax (TTM)Rs 49 Cr
Tax (latest year)Rs 9 Cr
Net profit (TTM)Rs 36 Cr
Net profit (latest year)Rs 30 Cr
Net profit (latest quarter)Rs 10 Cr
Depreciation (TTM)Rs 25 Cr
Depreciation (latest quarter)Rs 7 Cr
Interest (TTM)Rs 7 Cr
Cost of goods sold (latest year)Rs 132 Cr
Total expenditure (latest year)Rs 182 Cr
Total income (latest year)Rs 254 Cr
Share capitalRs 22 Cr
ReservesRs 302 Cr
Shareholders' fundsRs 325 Cr
Total assetsRs 481 Cr
Net blockRs 326 Cr
Capital work in progressRs 4 Cr
InvestmentsRs 0 Cr
ReceivablesRs 50 Cr
InventoryRs 70 Cr
Other liabilitiesRs 86 Cr
Shares outstanding (crore)2.23
Ownership
Promoter holding52.52% (-0.34 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 66.3 is at the 96th percentile of its own 9.4-year range (median 35.3, low 12.8, high 74.4).
P/B 7.37 is at the 98th percentile (median 3.11).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodSAKARNifty 50Difference
1 week-4.7%-2.8% -2.0 pts
1 month+11.3%-6.8% +18.1 pts
3 months+26.6%-7.6% +34.3 pts
6 months+115.7%+0.4% +115.3 pts
1 year+193.2%-9.9% +203.1 pts
2 years+236.0%-13.6% +249.5 pts
3 years+215.8%+14.2% +201.6 pts
5 years+568.7%+27.9% +540.8 pts

Red flags

F-score 6 of 8
lookOn NSE surveillance On NSE surveillance: ASM long-term
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹73 Cr +37.7% vs Jun 2025. Net profit ₹10 Cr +100.0%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2024-09-13Annual General Meeting
2023-09-14Annual General Meeting
2022-09-12Annual General Meeting
2021-09-16 Annual General Meeting
2020-09-16 Annual General Meeting
2019-09-06 Annual General Meeting
DateTypeWhat it says
2026-09-22AppointmentAppointment of M/s. Kashyap R. Mehta & Partners as Secretarial Auditors of the Company for the term of 5 years w.e.f. September 22, 2026.
2026-09-22Shareholder meetingVoting results.
2026-09-22Shareholder meetingProceedings of Annual General Meeting held on September 22, 2026
2026-09-14Concall / analyst meetSchedule of meet on 18th Sept., 2026
2026-09-14Concall / analyst meetSchedule of meet on 17th Sept., 2026
2026-09-01General UpdatesSakar receives 14 oncology product new approvals in the EU (Europe), UK & Canada with 7 business partners
2026-08-27Shareholder meetingNotice of Annual General Meeting to be held on September 22, 2026
2026-08-03Concall / analyst meetTranscript of Con-Call.
2026-07-29Concall / analyst meetLink of Recording
2026-07-28Investor PresentationInvestor Presentation
2026-07-24Concall / analyst meetSchedule of meet/Conference Call.
2026-07-24Press ReleaseA press release dated July 24, 2026, titled "Consolidated and Standalone Un-audited Financial Results for the quarter ended June 30, 2026".
2026-07-24Board meeting outcomeSakar Healthcare Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-20General UpdatesThe intimation of Board Meeting for taking on record Unaudited Financial Results for the quarter ended on 30th June, 2026 and other matter.
2026-07-09Disclosure under SEBI TakeovCobra India (Mauritius) Ltd  has submitted to  the Exchange a copy of Disclosure under Regulation 29(1) of Securities and Exchange Board of India (Sub...
2026-07-08General UpdatesCertificate under Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended 30th June 2026
2026-06-13Reply to Clarification- FinaThe Exchange had sought clarification from Sakar Healthcare Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listi...
2026-05-22Clarification - Financial ReThe Exchange has sought clarification from Sakar Healthcare Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listi...
2026-05-22Concall / analyst meetTranscript
2026-05-21General UpdatesSakar enters it s 40th agreement signed with Zydus Lifesciences to cater oncology products to GCC and other emerging markets, in parallel to building ...
2026-05-19Disclosure under SEBI TakeovSanjay S. Shah has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Ac...
2026-05-16Concall / analyst meetLink of the audio recording of Conference call with all the participants held on 15th May 2026, on Audited financial results of the Company for the qu...
2026-05-13Investor PresentationInvestor Presentation
2026-05-13Press ReleaseA press release dated May 12, 2026, titled "Press Release - Consolidated and Standalone Audited Financial Results for the quarter and year ended March...
2026-05-12Board meeting outcomeSakar Healthcare Limited has submitted to the Exchange, declaration with respect to non-applicability of Large Entities framework.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Long Term Additional Surveillance Measure (Long Term ASM): stage 1Scrip PE is greater than 50 (4 trailing quarters)
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03